Bespak manufactures a wide range of specialty medical drug delivery devices.
Although Bespak has historically focused on drug delivery devices for use in the treatment of asthma and COPD with the provision of metered dose inhalers (MDI) and dry powder inhalers (DPI), it is extending its reach to include nasal drug delivery devices, auto-injectors, nicotine delivery devices, and point-of-care diagnostic devices.
Bespak's range of currently marketed products includes the following key products:
1 Metered Dose Inhaler
Bespak is a global leader in supply of MDI valves serving major branded Life Sciences and generics companies. Bespak uniquely offers its own proprietary clean rubber technology and rubbers for use in its valves. Bespak has to date manufactured over one billion hydroflouroalkane (HFA) valves which is a significant achievement given the fact that the CFC (Chlorofluorocarbon) to HFA propulsion transition only occurred in the early/mid 2000s.
2 Integrated Dose Counter
Bespak operates in highly regulated markets with increasing regulatory requirements and hurdles. One such is the FDA requirement for low dose indication of MDIs and DPIs. Bespak offers a proprietary fully integrated (numeric) dose counter which has already been launched with Teva Pharmaceuticals. Moreover, Bespak has further programmes in development with major regional and global Life Sciences companies.
3 GSK's Diskus Device
Since its launch, Bespak has been and remains a major manufacturer of GSK's Diskus DPI. The device forms part of the world's largest respiratory franchise for the treatment of asthma and COPD. Bespak has partnered with GSK since the early 1990s. Bespak has to date manufactured over 600 million Diskus devices.
4 Chiesi's Foster NEXThaler®
This device has regulatory approval in 14 European markets and was launched in Germany in March 2013. The device, in development at Bespak since 2005, is a unique breath-actuated DPI. Bespak is currently engaged in further capacity increases, beyond that installed in 2012, to support the upcoming planned launches in further European territories.
5 Auto-safety injector (ASI)
This device was acquired with the Medical House in 2009, and development culminated in the first regulatory approval and launch of the product for Dr. Reddy's sumatriptan in February 2014. Further development opportunities are in progress for the product, including INJ570 which is on the Development Portfolio, and is currently undergoing regulatory approval.
6 Products in Development
Bespak is currently working with a number of European and global Life Sciences companies to develop respiratory, injectable, nasal, nicotine inhalation, and point-of-care diagnostics devices. Information on these programmes is summarised in the Bespak product development pipeline chart.